> Salix Pharmaceuticals is hoping it can delay a generic competitor to its most lucrative pharmaceutical. Report
> ViroPharma has added a fresh set of complaints to the objections being raised against a generic competitor to its antibiotic Vancocin. The drug developer says that the agency should require clinical studies to establish bioequivalence. Allowing laboratory work alone would significantly reduce the time it would take to gain approval. Report
> IVREA Pharmaceuticals has raised $11 million in new venture funds. Report
> Abbott Laboratories and AstraZeneca have inked a deal to develop a combinational therapy for cholesterol. Report
> Shares of Tercica jumped on the news that a federal court has ruled that its patents on Increlex are valid. Report
> Symphony Medical has begun a Phase II trial of a therapy for post-operative atrial fibrillation. Release
And Finally... Ian Wilmut, a leading expert on cloning, notes that the absence of a cloned primate underscores just how difficult it would be to clone a human. Report